Fonteneau Jean-François, Guillerme Jean-Baptiste, Tangy Frédéric, Grégoire Marc
INSERM; UMR892; Nantes, France ; CNRS; UMR6299; Nantes, France ; Université de Nantes; Nantes, France.
Oncoimmunology. 2013 May 1;2(5):e24212. doi: 10.4161/onci.24212.
Attenuated measles viruses (MV) are assessed in clinical trials for their capacity to preferentially infect and kill tumor cells. We recently showed that MV-infected tumor cells are able to activate tumor antigen cross-presentation by myeloid and plasmacytoid dendritic cells. Thus, MV-based antitumor virotherapy may stimulate antitumor immune response.
减毒麻疹病毒(MV)正在临床试验中评估其优先感染和杀死肿瘤细胞的能力。我们最近发现,感染MV的肿瘤细胞能够激活髓样和浆细胞样树突状细胞的肿瘤抗原交叉呈递。因此,基于MV的抗肿瘤病毒疗法可能会刺激抗肿瘤免疫反应。